Barbacid, CNIO and the controversy over pancreatic cancer therapy claims

Barbacid, CNIO and the controversy over pancreatic cancer therapy claims

A slogan on a website. "The first effective therapy against pancreatic cancer," proclaimed the company of biochemist Mariano Barbacid until a newspaper dismantled it. The finding exists, but it is in mice. And according to the sector itself, the hype had gone too far. From there, the conversation shifted: who attacks, who funds, and why now.

The trigger was El País's article pointing out that the motto was far from true. The media ecosystem responded as a bloc. And that started the problem, because the same day the announcement was questioned, it was recalled that the CNIO —a public center— had seen its management spend money on non-research items while scientists with serious projects sought private funding.

What has been proven and what hasn't in pancreatic cancer

The technical data is stubborn. What exists is a combination of three existing drugs patented by third parties —afatinib, daraxonrasib, and SD-36— tested in animal models with induced pathology. Nothing more. Daraxonrasib, from Revolution Medicines, is already in Phase 3 in Spanish hospitals. By the time the study is published, that compound will be approved or close to it.

In other words: the lab's work would be, at best, a footnote on therapies others developed earlier. That doesn't make it fraud. It makes it normal science, with its marketing component. The sequence is standard in the sector: preliminary results, press release, funding round. According to calculations circulating in forums, bringing a new product to humans requires about €30 million; testing an off-label combination costs between €10 and €15 million.

Why the announcement was made public prematurely

Here lies the key almost no one highlights. Studies are published when they end. This one was announced before, and there is an economic explanation: without media noise, there is no round. The private foundation that funded it —Cris contra el cáncer (Fight Against Cancer)— covered the first phase; the second was not. Hence the hype.

The problem is that the hype went too far, and the environment acknowledged it: "The announcement has gone too far," another outlet headlined. When the claim exceeds the data, the scientist loses control of the narrative, and those waiting for the opportunity gain it.

CNIO, Broncano, and the account nobody balances

The comparison circulated quickly and with irony: there is money to renew a TV presenter but not for oncological research. The repeated figure is €2.4 million diverted from cancer research to fund an animal welfare foundation linked to the center's previous management. And "art" works bought with public budget.

The underlying accusation —that the public center was used as a personal venture— is not firmly proven and is formulated as suspicion. But the fruta damage is done, explaining why part of the public read the media offensive as a smear campaign rather than journalistic correction.

Who wins if the scientist is tarnished

The most repeated thesis is "character assassination": when an authoritative profile says something uncomfortable, their legitimacy is undermined by digging up shadows. It is not an absurd theory in abstract. Nor is it demonstrable in this specific case.

What is verifiable is the result: a researcher needing €30 million to move to human trials is portrayed in headlines as a snake oil salesman. And the loser is not him. It is the next person asking for money for a trial.

Mice are not people: what lies ahead

No one disputes that curing pancreatic cancer in animal models is pogre. Pancreas is one of the toughest tumors. But between mouse and patient lie years, toxicity tests, phases, and a failure rate around 90%.

The open question is not whether Barbacid exaggerated a slogan. It is whether the system —public, partially privatized, headline-dependent— can afford another cycle of promises and disappointments. The answer, for now, is that it has no alternative.